Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.47 |
| ▸ | RAB9A | P51151 | 5/20 | 0.47 |
| ▸ | NAMPT | P43490 | 14/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.46 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.46 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4789524 | 0.86 | RAB9A (0.59) | NPC1RAB9ANAMPTTAS1R3TAS1R1 | |
| SCHEMBL4790954 | 0.79 | NAMPT (0.47) | NAMPT | |
| SCHEMBL4718481 | 0.78 | PTGDR2 (0.38) | NPC1RAB9ANAMPTMAPTALDH1A1 | |
| SCHEMBL4715261 | 0.74 | NAMPT (0.40) | NAMPT | |
| SCHEMBL14221973 | 0.74 | NAMPT (0.46) | NPC1RAB9ANAMPTSMN1; SMN2ATM | |
| SCHEMBL4791121 | 0.74 | CACNA1G (0.47) | NAMPT | |
| SCHEMBL3709542 | 0.73 | NAMPT (0.71) | NPC1RAB9ANAMPTTAS1R3TAS1R1 | |
| SCHEMBL3700363 | 0.72 | RAB9A (0.78) | NPC1RAB9ANAMPTTAS1R3TAS1R1 | |
| SCHEMBL4760965 | 0.72 | NAMPT (0.45) | NAMPT | |
| SCHEMBL4714943 | 0.71 | NR1H2 (0.56) | NPC1RAB9ANAMPTMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216230-B1 | FUSED CYCLOHEPTANE AND FUSED AZACYCLOHEPTANE COMPOUNDS AND THEIR USE AS INTEGRIN RECEPTOR ANTAGONISTS | AMGEN INC (US) | 2008-04-23 | — | — | EP | disclosed |
| US-6514964-B1 | Treating diseases, conditions or disorders mediated by integrin receptors, such as vitronectin and fibronectin receptors | AMGEN INC. | 2003-02-04 | — | — | US | disclosed |